The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin
Open accessAbstract
Intrinsic resistance to cytotoxic drugs has been a main issue in cancer therapy for decades. Microenvironmental acidity is a simple while highly efficient mechanism of chemoresistance, exploited through impairment of drug delivery. The latter is achieved by extracellular protonation and/or sequestration into acidic vesicles. This study investigates the importance of extracellular acidosis and nanovesicle (exosome) release in the resistance of human tumour cell to cisplatin (CisPt); in parallel to proton pump inhibitors (PPI) ability of interfering with these tumour cell features. The results showed that CisPt uptake by human tumour cells was markedly impaired by low pH conditions. Moreover, exosomes purified from supernatants of these cell cultures contained various amounts of CisPt, which correlated to the pH conditions of the culture medium. HPLC-Q-ICP-MS analysis revealed that exosome purified from tumour cell culture supernatants contained CisPt in its native form. PPI pre-treatment increased cellular uptake of CisPt, as compared to untreated cells, in an acidic-depend manner. Furthermore, it induced a clear inhibition of exosome release by tumour cells. Human tumours obtained from xenografts pretreated with PPI contained more CisPt as compared to tumours from xenografts treated with CisPt alone. Further analysis showed that in vivo PPI treatment induced a clear reduction in the plasmatic levels of tumour-derived exosomes which also contained lower level of CisPt. Altogether, these findings point to the identification of a double mechanism that human malignant melanoma use in resisting to a dreadful cellular poison such as cisplatin. This framework of resistance includes both low pH-dependent extracellular sequestration and an exosome-mediated elimination. Both mechanisms are markedly impaired by proton pump inhibition, leading to an increased CisPt-dependent cytotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
B lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546 · cited 1×
“Supernatants from human melanoma cell lines were harvested from 70–75% confluent cell cultures after 3 days in culture and isolated as previously described [32].”
MethodMicroenvironmental pH Is a Key Factor for Exosome Traffic in Tumor Cells
Parolini, I., Federici, C., Raggi, C., Lugini, L., Palleschi, S., De Milito, A., Coscia, C., Iessi, E., Logozzi, M., Molinari, A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.041152 · Cited by 1,555
Self-citationMelanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371 · cited 1×
“Single agent or combined chemotherapies result in poor benefits for patients with malignant melanoma [1], [2].”
BackgroundExosomal-like vesicles are present in human blood plasma
Caby, M.-P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G., & Bonnerot, C. (2005) · International Immunology · doi:10.1093/intimm/dxh267 · Cited by 1,343
Geran, R. I., Greenberg, N. H., MacDonald, M., Schumacher, A., & Abbott, B. J. (1972) · Cancer chemotherapy reports. Part 1 · Cited by 1,128
High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients
Logozzi, M., De Milito, A., Lugini, L., Borghi, M., Calabrò, L., Spada, M., Perdicchio, M., Marino, M. L., Federici, C., Iessi, E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005219 · Cited by 960
Self-citationManagement of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 855
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011624 · Cited by 774
Self-citationChapman, P. B., Einhorn, L. H., Meyers, M. L., Saxman, S., Destro, A. N., Panageas, K. S., Begg, C. B., Agarwala, S. S., Schuchter, L. M., Ernstoff, M. S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2745 · Cited by 764
Body fluid derived exosomes as a novel template for clinical diagnostics
Keller, S., Ridinger, J., Rupp, A.-K., Janssen, J. W., & Altevogt, P. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-86 · Cited by 751
Platinum neurotoxicity pharmacogenetics
McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0840 · Cited by 574
Safaei, R., Larson, B. J., Cheng, T. C., Gibson, M. A., Otani, S., Naerdemann, W., & Howell, S. B. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0102 · Cited by 564
Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs
Luciani, F., Spada, M., De Milito, A., Molinari, A., Rivoltini, L., Montinaro, A., Marra, M., Lugini, L., Logozzi, M., Lozupone, F., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh305 · Cited by 435
Self-citationCellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
Andrews, P. A., & Howell, S. B. (1990) · PubMed · Cited by 397
Tumor acidity, ion trapping and chemotherapeutics
Mahoney, B. P., Raghunand, N., Baggett, B., & Gillies, R. J. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00467-2 · Cited by 364
Enhancement of chemotherapy by manipulation of tumour pH
Raghunand, N., He, X., Sluis, R. V., Mahoney, B., Baggett, B., Taylor, C. W., Paine-Murrieta, G., Roe, D., Bhujwalla, Z. M., & Gillies, R. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690455 · Cited by 316
De Milito, A., Iessi, E., Logozzi, M., Lozupone, F., Spada, M., Marino, M. L., Federici, C., Perdicchio, M., Matarrese, P., Lugini, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4095 · Cited by 301
Self-citationVacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells
Martinez-Zaguilan, R., Lynch, R. M., Martinez, G. M., & Gillies, R. J. (1993) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1993.265.4.c1015 · Cited by 291
Intracellular pH and the control of multidrug resistance.
Simon, S., Roy, D., & Schindler, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.3.1128 · Cited by 276
De Milito, A., Canese, R., Marino, M. L., Borghi, M., Iero, M., Villa, A., Venturi, G., Lozupone, F., Iessi, E., Logozzi, M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25009 · Cited by 274
Self-citationTumor Acidity, Chemoresistance and Proton Pump Inhibitors
De Milito, A., & Fais, S. (2005) · Future Oncology · doi:10.2217/14796694.1.6.779 · Cited by 265
Self-citationTargeting Vacuolar H+-ATPases as a New Strategy against Cancer
Fais, S., De Milito, A., You, H., & Qin, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1805 · Cited by 264
Self-citationChemotherapy for metastatic melanoma: Time for a change?
Gogas, H. J., Kirkwood, J. M., & Sondak, V. K. (2007) · Cancer · doi:10.1002/cncr.22427 · Cited by 223
Elevated expression of vacuolar proton pump genes and cellular ph in cisplatin resistance
Murakami, T., Shibuya, I., Ise, T., Chen, Z., Akiyama, S., Nakagawa, M., Izumi, H., Nakamura, T., Matsuo, K., Yamada, Y., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1418 · Cited by 144
Safaei, R., Katano, K., Larson, B. J., Samimi, G., Holzer, A. K., Naerdemann, W., Tomioka, M., Goodman, M., & Howell, S. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.756.11.2 · Cited by 141
Raghunand, N., Martínez–Zaguilán, R., Wright, S. H., & Gillies, R. J. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00021-0 · Cited by 139
Li, W., & Melton, D. W. (2011) · Oncogene · doi:10.1038/onc.2011.426 · Cited by 131
Fan, S., Niu, Y., Tan, N. S., Wu, Z., Wang, Y., You, H. S., Ke, R., Song, J., Shen, Q., Wang, W., et al. (2012) · Oncogene · doi:10.1038/onc.2012.183 · Cited by 112
Proton pump inhibitor‐induced tumour cell death by inhibition of a detoxification mechanism
Fais, S. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02225.x · Cited by 107
Self-citationReduced endocytosis and altered lysosome function in cisplatin-resistant cell lines
Chauhan, S. S., Liang, X., Su, A. W., Panandiker, A. S. P., Shen, D. W., Hanover, J. A., & Gottesman, M. M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600861 · Cited by 90
Spugnini, E. P., Baldi, A., Buglioni, S., Carocci, F., de Bazzichini, G. M., Betti, G., Pantaleo, I., Menicagli, F., Citro, G., & Fais, S. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-221 · Cited by 87
Self-citationAnimal pharmacodynamics of omeprazole. A survey of its pharmacological propertiesin vivo
Larsson, H., Mattson, H., Sundell, G., & Carlsson, E. I. (1985) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528509095817 · Cited by 86
Proton pump inhibitors may reduce tumour resistance
Milito, A. D., & Fais, S. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.7.1049 · Cited by 77
Self-citationNovel strategies for reversing platinum resistance
Shahzad, M. M. K., Lopez‐Berestein, G., & Sood, A. K. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.09.001 · Cited by 77
Ouar, Z., Lacave, R., Bens, M., & Vandewalle, A. (1999) · Cell Biology and Toxicology · doi:10.1023/a:1007521430236 · Cited by 55
Eton, O. E., Ross, M. I., East, M. J., Mansfield, P. F., Papadopoulos, N., Ellerhorst, J. A., Bedikian, A. Y., & Lee, J. E. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-9 · Cited by 51
Ichihashi, N., & Kitajima, Y. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04129.x · Cited by 46
Murine granulocytes control human tumor growth in SCID mice
Lozupone, F., Luciani, F., Venditti, M., Rivoltini, L., Pupa, S. M., Parmiani, G., Belardelli, F., & Fais, S. (2000) · International Journal of Cancer · Cited by 27
Self-citation
Cited by
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
Becker, A., Thakur, B. K., Weiss, J. M., Kim, H. S., Peinado, H., & Lyden, D. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.009 · Cited by 2,003
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
“EGFR-induced tumor mitigation in patients with breast cancer [131].”
BackgroundThe biology and function of exosomes in cancer
Kalluri, R. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81135 · Cited by 1,849
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.30087 · Cited by 1,491
Self-citationThe Science and Translation of Lactate Shuttle Theory
Brooks, G. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.008 · Cited by 1,486
Metadata
- Authors
- Federici, C., Petrucci, F., Caimi, S., Cesolini, A., Logozzi, M., Borghi, M., D'Ilio, S., Lugini, L., Violante, N., Azzarito, T., Majorani, C., Brambilla, D., & Fais, S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-06
- Volume
- 9
- Issue
- 2
- Pages
- e88193
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2081371902
- Cited by
- 354
- References
- 39
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.